Skip to main content

Table 4 Effect of VSL#3® on fibrosis risk scores

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

 

Number of patients pre-VSL#3®

Number of patients post-VSL#3®

p valuea

F0–F2

Indeterminate

F3–F4

F0–F1

Indeterminate

F3–F4

 

NAFLD fibrosis risk score

1

11

7

3

9

7

0.16

FIB4 index

8

7

4

8

9

2

0.41

  1. n = 19
  2. F0–F2 = absence of significant fibrosis
  3. F3–F4 = presence of significant fibrosis
  4. aWilcoxon signed rank test
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us